BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 12703009)

  • 21. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.
    Miyakubo M; Oriuchi N; Tsushima Y; Higuchi T; Koyama K; Arai K; Paudyal B; Iida Y; Hanaoka H; Ishikita T; Nakasone Y; Negishi A; Mogi K; Endo K
    Ann Nucl Med; 2007 Feb; 21(2):129-35. PubMed ID: 17424980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
    Garcia R; Kim EE; Wong FC; Korkmaz M; Wong WH; Yang DJ; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1476-9. PubMed ID: 8790197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.
    Yen TC; Ng KK; Ma SY; Chou HH; Tsai CS; Hsueh S; Chang TC; Hong JH; See LC; Lin WJ; Chen JT; Huang KG; Lui KW; Lai CH
    J Clin Oncol; 2003 Oct; 21(19):3651-8. PubMed ID: 14512397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
    Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
    Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study.
    Golan S; Sopov V; Baniel J; Groshar D
    J Urol; 2011 Aug; 186(2):436-41. PubMed ID: 21679983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
    Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
    J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
    Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
    J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer.
    Lapela M; Eigtved A; Jyrkkiö S; Grénman R; Kurki T; Lindholm P; Nuutinen J; Sutinen E; Solin O; Bjornskov I; Bretlau P; Friberg L; Holm S; Jensen M; Sand Hansen H; Minn H
    Eur J Cancer; 2000 May; 36(7):858-67. PubMed ID: 10785590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbon-11 choline or FDG-PET for staging of oesophageal cancer?
    Jager PL; Que TH; Vaalburg W; Pruim J; Elsinga P; Plukker JT
    Eur J Nucl Med; 2001 Dec; 28(12):1845-9. PubMed ID: 11734925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
    Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
    Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
    Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
    Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.
    Aoki J; Watanabe H; Shinozaki T; Takagishi K; Ishijima H; Oya N; Sato N; Inoue T; Endo K
    Radiology; 2001 Jun; 219(3):774-7. PubMed ID: 11376267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.